References
- Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001;22:2267-74. https://doi.org/10.1053/euhj.2001.2896
- Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart. J Mol Cell Cardiol 1998;30:A112.
- Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol 1993; 21:128-35. https://doi.org/10.1097/00005344-199301000-00019
- American Heart Association. 1999 heart and stroke statistical update. Chicago: American Heart Association;1999.
- Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000;342:1163-70. https://doi.org/10.1056/NEJM200004203421603
- Rosano GM, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2006;98: 14J-8J.
- Marazzi G, Wajngarten M, Vitale C, et al. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. Int J Cardiol 2007;120:79-84. https://doi.org/10.1016/j.ijcard.2006.08.082
- Nakamura S, Naruse M, Naruse K, et al. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes. Am J Hypertens 1991;4:909-12. https://doi.org/10.1093/ajh/4.11.909
- Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464-9. https://doi.org/10.1161/01.CIR.87.2.464
- White HD, French JK. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 2003;42:1917-20. https://doi.org/10.1016/j.jacc.2003.09.006
- Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002; 40:437-45. https://doi.org/10.1016/S0735-1097(02)01986-1
- Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 2004;20:1447-54. https://doi.org/10.1185/030079904X2637
- Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-8. https://doi.org/10.1161/01.RES.86.5.580
- Banach M. The role of trimetazidine in the treatment of heart diseases. Ponzan, Poland: Termedia Publishing House;2006. p.52-6.
- Blardi P, de Lalla A, Volpi L, Auteri A, Di Perri T. Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning? Pharmacol Res 2002;45:69-72. https://doi.org/10.1006/phrs.2001.0905
- Lopez N, Varo N, Diez J, Fortuno MA. Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists? Cardiovasc Res 2007;75:536-45. https://doi.org/10.1016/j.cardiores.2007.04.025
- Stanley WC. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Investig Drugs 2002;11:615-29. https://doi.org/10.1517/13543784.11.5.615
- Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006;48:992-8. https://doi.org/10.1016/j.jacc.2006.03.060
- Labrou A, Giannoglou G, Zioutas D, Fragakis N, Katsaris G, Louridas G. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 2007;7:143-50. https://doi.org/10.2165/00129784-200707020-00006
Cited by
- Trimetazidine and Cardioprotection : Facts and Perspectives vol.66, pp.3, 2013, https://doi.org/10.1177/0003319714530040
- Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis vol.10, pp.9, 2013, https://doi.org/10.1371/journal.pone.0137775
- Trimetazidine in the Prevention of Tissue Ischemic Conditions vol.70, pp.4, 2013, https://doi.org/10.1177/0003319718780551
- Efficacy of Trimetazidine in Limiting Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis vol.72, pp.6, 2013, https://doi.org/10.1177/0003319720987745